US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences, in a deal worth up to US$2.18 billion.
Gilead Sciences is among a group of global drug makers facing patent expirations and turning to mergers, acquisitions and licensing deals to refill their drug pipelines.
Under the agreement, Gilead Sciences would pay shareholders of US-based Ouro Medicines US$1.675 billion…
Rights to antibody drug from China’s Keymed change hands in Gilead acquisition of Ouro
